Effect of immunosuppressive therapy in infl ammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F22%3AN0000026" target="_blank" >RIV/00209775:_____/22:N0000026 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/22:00075821 RIV/00216224:14110/22:00128010

Výsledek na webu

<a href="http://www.elis.sk/download_file.php?product_id=7503&session_id=p837ql6mq8aer9601ekbmlrve6" target="_blank" >http://www.elis.sk/download_file.php?product_id=7503&session_id=p837ql6mq8aer9601ekbmlrve6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/BLL_2022_006" target="_blank" >10.4149/BLL_2022_006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of immunosuppressive therapy in infl ammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial.

Popis výsledku v původním jazyce

INTRODUCTION: The indications for specifi c treatment in the cases of infl ammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with infl ammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy-proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically signifi cant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35). Text in PDF www.elis.sk

Název v anglickém jazyce

Effect of immunosuppressive therapy in infl ammatory cardiomyopathy: data from The Czech Inflammatory Cardiomyopathy Immunosuppressive Trial.

Popis výsledku anglicky

INTRODUCTION: The indications for specifi c treatment in the cases of infl ammatory cardiomyopathy are based on limited data from several small clinical trials. AIM: A comparison of the effect of two dose regimens of combined immunosuppressive therapy by adding them to conventional heart failure therapy and comparing them with conventional heart failure therapy alone in patients with infl ammatory cardiomyopathy. METHODS AND STUDY POPULATION: We enrolled 20 patients; mean age 46.10±7.33 years, duration of symptoms <6 months, LVEF ≤40 %, NYHA class II–IV, with biopsy-proven myocarditis. Patients were randomly separated into groups treated with immunosuppressive therapy in addition to conventional heart failure therapy or to a group treated with conventional heart failure therapy alone. Clinical and echocardiographic parameters were evaluated. RESULTS: The baseline values of LVEF in the group of immunosuppressive therapy (LVEF 22.3±4.7 %) were similar to those in the group treated with conventional heart failure therapy (LVEF 21.7±4.7 %; p=0.757). After twelve months there was no statistically signifi cant difference in LVEF between the two studied groups (LVEF 33.7±9.5 % for the immunosuppressive therapy group and 41.3±13.0 % for the conventional therapy group; p=0.175). CONCLUSION: In our study population, we proved no positive effect of combined immunosuppressive therapy on the left ventricular function over 12 months. The main limitation of the study is the small number of enrolled patients (Tab. 4, Fig. 1, Ref. 35). Text in PDF www.elis.sk

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislava Medical Journal

ISSN

0006-9248

e-ISSN

1336-0345

Svazek periodika

123

Číslo periodika v rámci svazku

1.1.2022

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

7

Strana od-do

37-43

Kód UT WoS článku

000748938700006

EID výsledku v databázi Scopus

2-s2.0-85123036945